Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069753 | 0.84 | SLC6A3 (0.48) | HTR3ASLC6A3SLC6A2CHRNA7SLC6A4 | |
| SCHEMBL20054226 | 0.83 | CTSL (0.30) | — | |
| SCHEMBL263978 | 0.82 | HTR3A (0.53) | HTR3ASLC6A3SLC6A2CHRNA7SLC6A4 | |
| SCHEMBL1673686 | 0.82 | HTR3A (0.53) | HTR3ASLC6A3SLC6A2CHRNA7SLC6A4 | |
| Hydrochloric Acid SCHEMBL1673491 | 0.80 | HTR3A (0.52) | HTR3ASLC6A3SLC6A2CHRNA7SLC6A4 | |
| Hydrochloric Acid SCHEMBL1673492 | 0.80 | HTR3A (0.52) | HTR3ASLC6A3SLC6A2CHRNA7SLC6A4 | |
| Hydrochloric Acid SCHEMBL2031988 | 0.80 | HTR3A (0.52) | HTR3ASLC6A3SLC6A2CHRNA7SLC6A4 | |
| SCHEMBL11502447 | 0.79 | TSHR (0.33) | SLC6A3SLC6A2 | |
| SCHEMBL27587922 | 0.79 | CYP19A1 (0.35) | MEN1KMT2A | |
| SCHEMBL27971317 | 0.79 | ESR2 (0.41) | HTR3AHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105358132-A | Abuse resistant capsules | RP SCHERER TECHNOLOGIES LLC | 2016-02-24 | — | — | CN | claimed |
| US-20180098970-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| EP-2307011-B1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| CN-105963676-A | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-102858361-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-105682649-A | Compositions and methods for reducing overdose | 艾萨·欧蒂迪 | 2016-06-15 | — | — | CN | disclosed |
| CN-105358132-A | Abuse resistant capsules | RP SCHERER TECHNOLOGIES LLC | 2016-02-24 | — | — | CN | disclosed |
| CN-104968333-A | Self-regulated release of active pharmaceutical ingredients | ACURA PHARMACEUTICALS INC | 2015-10-07 | — | — | CN | disclosed |
| CN-104013620-A | Mazindol combination in treatment of attention deficit/hyperactivity | ASSIST PUBL HOPITAUX DE PARIS | 2014-09-03 | — | — | CN | disclosed |
| CN-102292826-A | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2009155139-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| CN-101420953-A | Combination of mazindols in the treatment of attention deficit/hyperactivity disorder | ASSIST PUBL HOPITAUX DE PARIS (FR) | 2009-04-29 | — | — | CN | disclosed |
| CN-101272788-A | Melanocortin receptor-specific piperazine compounds with diamine groups | PALATIN TECHNOLOGIES INC (US) | 2008-09-24 | — | — | CN | disclosed |
| CN-101272789-A | Melanocortin receptor-specific piperazine and ketone-piperazine compounds | PALATIN TECHNOLOGIES INC (US) | 2008-09-24 | — | — | CN | disclosed |
| CN-1863513-A | Abuse-proffed dosage form | GRUENENTHAL GMBH (DE) | 2006-11-15 | — | — | CN | disclosed |
| CN-1863514-A | Abuse-proffed dosage form | GRUENENTHAL GMBH (DE) | 2006-11-15 | — | — | CN | disclosed |
| CN-1816337-A | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES INC (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1179418-A | Novel cyloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 1998-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098970-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | INMT, PNMT, SLC6A2 | HTR3A 41/4885SLC6A3 6/4885SLC6A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.